Evidence network for deaths_(OS)

1IMpassion-130 (PDL1>1%), 20182KEYNOTE-355 (CPS>1), 2020 KEYNOTE-355 (CPS>10), 20201IMpassion-131 (PD-L1 > 1%), 20201TORCHLIGHT PDL 1 positive population, 2024atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel 0.64 [0.40; 1.03]0.64 [0.40;1.03]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel 0.64 [0.40; 1.03]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.87 [0.63; 1.19]0.87 [0.63;1.19]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.87 [0.63; 1.19]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.71 [0.54; 0.94]0.71 [0.54;0.94]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.71 [0.54; 0.94]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel 1.56 [0.97; 2.51]1.56 [0.97;2.51]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel 1.56 [0.97; 2.51]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC 1.36 [0.90; 2.05]1.36 [0.90;2.05]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC 1.36 [0.90; 2.05]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.11 [0.76; 1.63]1.11 [0.76;1.63]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.11 [0.76; 1.63]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.15 [0.84; 1.58]1.15 [0.84;1.58]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.15 [0.84; 1.58]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel 0.74 [0.49; 1.11]0.74 [0.49;1.11]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel 0.74 [0.49; 1.11]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.82 [0.70; 0.95]0.82 [0.70;0.95]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.82 [0.70; 0.95]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.41 [1.07; 1.86]1.41 [1.07;1.86]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.41 [1.07; 1.86]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.61; 1.32]0.90 [0.61;1.32]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.61; 1.32]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.22 [1.05; 1.43]1.22 [1.05;1.43]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.22 [1.05; 1.43]nab-paclitaxelStandard of Care (SoC)paclitaxelnab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelpembrolizumab plus SoCatezolizumab plus paclitaxelnab-paclitaxel plus toripalimabdirect evidencenetwork meta-analysis
T vs. C nab-paclitaxelStandard of Care (SoC)paclitaxelnab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelpembrolizumab plus SoCatezolizumab plus paclitaxelnab-paclitaxel plus toripalimab
nab-paclitaxel---NANANANANANANA
Standard of Care (SoC)NA---NANA1.41
1.07; 1.86		1.22
1.05; 1.43		0.90
0.61; 1.32		NA
paclitaxelNANA---NANANANANA
nab-paclitaxel plus placeboNANANA---NANANANA
atezolizumab plus nab-paclitaxelNA0.71
0.54; 0.94		NANA---0.87
0.63; 1.19		0.64
0.40; 1.03		NA
pembrolizumab plus SoCNA0.82
0.70; 0.95		NANA1.15
0.84; 1.58		---0.74
0.49; 1.11		NA
atezolizumab plus paclitaxelNA1.11
0.76; 1.63		NANA1.56
0.97; 2.51		1.36
0.90; 2.05		---NA
nab-paclitaxel plus toripalimabNANANANANANANA---

pathologies: 143 - treatments: 1575 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons